Table 1.
Basic characteristics of the studies included in the comparison of mild and moderate to severe pulmonary hypertension
| author | year | Number of patients | population | study type | Age(mean, SD) | Nulli/multiparous(n) | Other medical problems(n) | NIH-QAT |
|---|---|---|---|---|---|---|---|---|
| CHEN Lin, et al. [25] | 2014 | 62 | Chinese | A retrospective cohort study | 28,3 | NR | NR | Fair |
| CHEN Yan, et al. [23] | 2019 | 75 | Chinese | A retrospective cohort study | Mild PAH = 29.89,5.66;Moderate PAH = 27.86, 5.01; Severe PAH = 28.33,5.52 | NR | NR | Good |
| CHEN Yihong, et al. [11] | 2012 | 37 | Chinese | A retrospective cohort study | 26.8,8.6 | 34/3 | NR | Good |
| FAN Shu, et al. [31] | 2020 | 47 | Chinese | A retrospective cohort study | Mild PAH = 28.72,5.71;Moderate PAH = 31.62, 8.10; Severe PAH = 22.75,3.32 | 36/16 | NR | Fair |
| GOOG Yunxia, et al. [12] | 2009 | 53 | Chinese | A retrospective cohort study | 27,4 | /12 | NR | Fair |
| HAN Cha, et al. [13] | 2013 | 118 | Chinese | A retrospective cohort study | 29,5 | 82/36 | NR | Good |
| HAO Jinhong, et al. [14] | 2013 | 36 | Chinese | A retrospective cohort study | 26.7,4.54 | NR | NR | Fair |
| Katsuragi Shinji, et al. [28] | 2012 | 24 | Japanese | A cohort study | Mild PAH = 29.5,3.5;Severe PAH = 30.1,4.0 | Mild PAH = 8/6;Severe PAH = 15/13 | Hypertension: Mild PAH = 2;Severe PAH = 3; DM: Mild PAH = 1, Severe PAH = 3 | Fair |
| Lai Weisi, et al. [26] | 2021 | 88 | Chinese | A retrospective cohort study | Moderate PAH = 28.6,6.3;Severe PAH = 28.1,5.7 | NR | NR | Fair |
| LI Bin, et al. [15] | 2013 | 102 | Chinese | A retrospective cohort study | 27,5 | NR | NR | Fair |
| LI Ning, et al. [37] | 2017 | 85 | Chinese | A retrospective cohort study | 32,7 | NR | NR | Fair |
| LIN Feng, et al. [16] | 2009 | 91 | Chinese | A retrospective cohort study | 25,3.2 | 73/18 | NR | Fair |
| LIN Jian-hua, et al. [35] | 2006 | 61 | Chinese | A retrospective cohort study | NR | NR | NR | Fair |
| LIN Li, et al. [17] | 2013 | 85 | Chinese | A retrospective cohort study | 26.2,8.5 | NR | NR | Fair |
| LIN Xiao, et al. [32] | 2020 | 151 | Chinese | A retrospective cohort study | 29.8,4.5 | NR | NR | Fair |
| Luo Jun et al. [27] | 2020 | 79 | Chinese | A cohort study | Mild PH = 26.6,5.7;Severe PH = 26.0,4.9 | Mild PH = 29/7;Severe PH = 33/10 | NR | Good |
| Subbaiah Murali, et al. [9] | 2013 | 30 | Indian | A cohort study | Mild PAH = 28.64, 4.09;Severe PAH = 28.02, 3.9 | Mild PAH = 10/6;Severe PAH = 8/6 | Hypertension: Mild PAH = 1;Severe PAH = 0; Hypothyroidism: Mild PAH = 1; Severe PAH = 3; DM: Mild PAH = 2, Severe PAH = 1 | Fair |
| WANG Wenjing, et al. [29] | 2015 | 79 | Chinese | A retrospective cohort study | 26.3, 4.58 | NR | NR | Fair |
| WEI Ming-zhu,et al. [36] | 2009 | 44 | Chinese | A retrospective cohort study | 26, 3 | 33/11 | NR | Fair |
| WU Yafeng, et al. [34] | 2020 | 130 | Chinese | A retrospective cohort study | 28.36, 5.41 | NR | NR | Fair |
| YANG Dong, et al. [18] | 2012 | 44 | Chinese | A retrospective cohort study | 29, 5 | 44 | NR | Fair |
| YE Jun, et al. [19] | 2010 | 18 | Chinese | A retrospective cohort study | NR | 16/2 | NR | Fair |
| YUE Jun, et al. [20] | 2011 | 43 | Chinese | A retrospective cohort study | 28.3 | 41/2 | NR | Fair |
| ZHANG Chengju, et al. [21] | 2018 | 64 | Chinese | A retrospective cohort study | 26.73, 5.67 | NR | NR | Good |
| ZHANG Xiao, et al. [22] | 2021 | 52 | Chinese | A retrospective cohort study | 28.7, 4.1 | 47/5 | NR | Fair |
| ZHAO Chuchu, et al. [30] | 2020 | 74 | Chinese | A retrospective cohort study | 25.7,4.66 | NR | NR | Fair |
| ZHOU Xiaorui, et al. [10] | 2013 | 149 | Chinese | A retrospective cohort study | 29.3, 5.7 | NR | NR | Good |
| Zhou Qian et al. [33] | 2021 | 60 | Chinese | A cohort study | Mild PH = 31.1, 2.3;Moderate PH = 29.3, 1.7; Severe PH = 26.2, 2.1 | NR | NR | Good |
| Zhu Cai-Xia et al. [24] | 2018 | 79 | Chinese | A cohort study | Mild PH = 30.9,5.4;Moderate PH = 30.7, 4.62; Severe PH = 26.8, 2.75 | Mild PH = 35/22;Moderate PH = 8/2; Severe PH = 7/4 | Pre-eclampsia: Mild PH = 7;Moderate PH = 1;Severe PH = 1; GDM: Mild PH = 11; Moderate PH = 1;Severe PH = 1; PROM: Mild PH = 5; Moderate PH = 2;Severe PH = 0; Placenta previa: Mild PH = 4; Moderate PH = 0;Severe PH = 0; Previous cesarean: Mild PH = 7; Moderate PH = 0;Severe PH = 1 | Good |
| Budhram S, et al. [38] | 2022 | 185 | South African | A retrospective study | Mild PH = 26(22–23),Moderate PH = 30(23–33),Severe PH = 27(26–33) | NR | HIV status: Mild PAH = 34;Moderate PAH = 28;Severe PAH = 8 | Good |
| Su J Y, et al. [39] | 2022 | 94 | Chinese | A retrospective study | 32.71,5.95 | 46/48 | NR | Good |
| Zhang Lin, et al. [40] | 2022 | 181 | Chinese | A retrospective study | Mild PH = 29(33–37),Moderate PH = 26(31–37),Severe PH = 24(30–34) | Mild PH = 32/101,Moderate PH = 11/31,Severe PH = 24/49 | Hypertension: Mild PH = 44; Moderate PH = 5; Severe PH = 7; Pre-eclampsia/eclampsia: Mild PH = 40; Moderate PH = 5; Severe PH = 4; HELLP syndrome :Mild PH = 1; Moderate PH = 0; Severe PH = 0; Diabetes mellitus: Mild PH = 10; Moderate PH = 1; Severe PH = 3; Autoimmune disease: Mild PH = 8; Moderate PH = 0; Severe PH = 3; Liver damage: Mild PH = 1; Moderate PH = 2; Severe PH = 2; Kindney injury: Mild PH = 5; Moderate PH = 1; Severe PH = 3; Others: Mild PH = 10; Moderate PH = 2; Severe PH = 3 | Good |